Mitsubishi UFJ Asset Management Co. Ltd. Invests $1.47 Million in The Chemours Company $CC

Key Points

• Mitsubishi UFJ Asset Management acquired 71,468 Chemours shares worth approximately $1.47 million, while institutional investors collectively own 76.26% of the company.
• Chemours missed its latest quarterly revenue and EPS expectations, reporting $0.42 EPS and $1.59 billion in revenue. Analysts subsequently lowered several near-term earnings forecasts, including Q3 2026 EPS from $0.41 to $0.25.
• Analysts maintain a consensus “Hold” rating with an average price target of $20.10, despite multiple target-price cuts. Company insiders have also purchased 8,663 shares worth about $130,601 over the past 90 days.

Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in The Chemours Company (NYSE:CC - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 71,468 shares of the specialty chemicals company's stock, valued at approximately $1,467,000.

Several other institutional investors and hedge funds have also modified their holdings of CC. Atlas Capital Advisors Inc. purchased a new stake in Chemours in the 4th quarter worth approximately $26,000. Aster Capital Management DIFC Ltd purchased a new position in shares of Chemours during the 4th quarter worth $28,000. Covestor Ltd boosted its holdings in shares of Chemours by 204.7% during the fourth quarter. Covestor Ltd now owns 2,602 shares of the specialty chemicals company's stock worth $31,000 after purchasing an additional 1,748 shares during the last quarter. Eurizon Capital SGR S.p.A. acquired a new stake in shares of Chemours during the fourth quarter worth $31,000. Finally, Rothschild Investment LLC grew its position in shares of Chemours by 87.0% in the fourth quarter. Rothschild Investment LLC now owns 2,698 shares of the specialty chemicals company's stock valued at $32,000 after purchasing an additional 1,255 shares during the period. Hedge funds and other institutional investors own 76.26% of the company's stock.

More Chemours News

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: Zacks raised its FY2027 EPS forecast to $2.05 from $1.95 and increased Q4 2027 EPS to $0.61 from $0.53, suggesting improved profitability may emerge beyond 2026.
• Positive Sentiment: The firm also lifted estimates for Q1 2027 EPS to $0.40 from $0.39, Q3 2027 EPS to $0.58 from $0.56, Q1 2028 EPS to $0.56 from $0.55, and Q2 2028 EPS to $0.65 from $0.61.
• Neutral Sentiment: The revisions indicate a potentially stronger longer-term earnings trajectory, but they are offset by weaker expectations for the company’s immediate results. Zacks’ current full-year EPS consensus is approximately $0.87.
• Negative Sentiment: Zacks cut its FY2026 EPS forecast to $0.83 from $0.90 and reduced Q4 2026 EPS to $0.11 from $0.12, signaling pressure on near-term earnings.
• Negative Sentiment: The largest revision was a reduction in Q3 2026 EPS to $0.25 from $0.41. That forecast implies a substantial decline from the previous estimate and could weigh on investor sentiment.
• Negative Sentiment: FY2028 EPS was also lowered to $2.31 from $2.38, indicating that longer-term optimism is not broad-based. Chemours recently missed quarterly revenue and EPS expectations, adding to concerns about operating momentum.

Analysts Set New Price Targets

CC has been the topic of several recent analyst reports. BMO Capital Markets reduced their target price on Chemours from $26.00 to $18.00 and set an "outperform" rating on the stock in a research report on Thursday, August 13th. JPMorgan Chase & Co. lowered their price target on Chemours from $22.00 to $15.00 and set a "neutral" rating for the company in a report on Thursday, August 13th. Royal Bank Of Canada dropped their price objective on shares of Chemours from $26.00 to $22.00 and set an "outperform" rating for the company in a research note on Thursday, August 6th. Truist Financial cut their price objective on shares of Chemours from $30.00 to $24.00 and set a "buy" rating on the stock in a report on Thursday, August 6th. Finally, Alembic Global Advisors reissued an "overweight" rating and issued a $30.00 target price on shares of Chemours in a research report on Wednesday, May 13th. Five investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $20.10.

Insider Buying and Selling

In other news, CFO Shane Hostetter acquired 3,350 shares of the stock in a transaction on Thursday, August 6th. The stock was bought at an average price of $14.94 per share, with a total value of $50,049.00. Following the completion of the transaction, the chief financial officer directly owned 102,698 shares of the company's stock, valued at $1,534,308.12. The trade was a 3.37% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Calderon Gerardo Familiar acquired 1,935 shares of the company's stock in a transaction dated Wednesday, August 12th. The shares were purchased at an average price of $15.53 per share, for a total transaction of $30,050.55. Following the purchase, the insider directly owned 58,547 shares of the company's stock, valued at approximately $909,234.91. This trade represents a 3.42% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders have purchased 8,663 shares of company stock valued at $130,601. Corporate insiders own 0.85% of the company's stock.

Chemours Stock Performance

Shares of CC stock opened at $15.96 on Friday. The company's fifty day simple moving average is $18.01 and its 200-day simple moving average is $20.01. The Chemours Company has a 52 week low of $10.44 and a 52 week high of $28.67. The company has a current ratio of 1.66, a quick ratio of 0.88 and a debt-to-equity ratio of 18.98. The company has a market cap of $2.40 billion, a PE ratio of -8.36 and a beta of 1.43.

Chemours (NYSE:CC - Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The specialty chemicals company reported $0.42 earnings per share for the quarter, missing analysts' consensus estimates of $0.49 by ($0.07). Chemours had a positive return on equity of 60.64% and a negative net margin of 5.00%.The business had revenue of $1.59 billion for the quarter, compared to analysts' expectations of $1.65 billion. During the same period last year, the company posted ($2.54) earnings per share. The firm's revenue for the quarter was down 1.5% on a year-over-year basis. As a group, equities research analysts anticipate that The Chemours Company will post 0.87 EPS for the current year.

Chemours Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 15th. Investors of record on Friday, August 14th will be issued a dividend of $0.0875 per share. This represents a $0.35 annualized dividend and a dividend yield of 2.2%. The ex-dividend date is Friday, August 14th. Chemours's dividend payout ratio (DPR) is presently -18.32%.

Chemours Profile

Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.

Chemours' principal business activities are organized into three core segments.

Want to see what other hedge funds are holding CC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Chemours Company (NYSE:CC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source